Evidence map›Paper›PMID 26637405›Full record

ReviewClinical science (London, England : 1979)2016

The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment.

Massimo Volpe, Marino Carnovali, Vittoria Mastromarino

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical science (London, England : 1979), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 5 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 5 syntheses or guidelines pooled it, 295 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Article
  11. One Syndrome, Many Faces: A Unified Perspective on Heart Failure Phenotypes.International journal of molecular sciences · 2025
    Review
  12. Review
  13. Biomarkers in Heart Failure: A Review and a Wish.International journal of molecular sciences · 2025
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. The Genetic Polymorphisms ofInternational journal of molecular sciences · 2025
    Article
  19. Review
  20. Downregulation ofCurrent diabetes reviews · 2025
    Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Massimo VolpeCardiology Department, Clinical and Molecular Medicine Department, Sapienza University of Rome, 00189 Rome, Italy IRCCS Neuromed, 86077 Pozzilli, IS, Italy massimo.volpe@uniroma1.it.
Marino CarnovaliRehabilitation Department, A.O. "G. Salvini" 20024 Garbagnate Milanese, Milan, Italy.
Vittoria MastromarinoCardiology Department, Clinical and Molecular Medicine Department, Sapienza University of Rome, 00189 Rome, Italy.
Istituto Neurologico Mediterraneo · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After its discovery in the early 1980s, the natriuretic peptide (NP) system has been extensively characterized and its potential influence in the development and progression of heart failure (HF) has been investigated. HF is a syndrome characterized by the activation of different neurohormonal systems, predominantly the renin-angiotensin (Ang)-aldosterone system (RAAS) and the sympathetic nervous system (SNS), but also the NP system. Pharmacological interventions have been developed to counteract the neuroendocrine dysregulation, through the down modulation of RAAS with ACE (Ang-converting enzyme) inhibitors, ARBs (Ang receptor blockers) and mineralcorticoid antagonists and of SNS with β-blockers. In the last years, growing attention has been paid to the NP system. In the present review, we have summarized the current knowledge on the NP system, focusing on its role in HF and we provide an overview of the pharmacological attempts to modulate NP in HF: from the negative results of the study with neprilysin (NEP) inhibitors, alone or associated with an ACE inhibitor and vasopeptidase inhibitors, to the most recently and extremely encouraging results obtained with the new pharmacological class of Ang receptor and NEP inhibitor, currently defined ARNI (Ang receptor NEP inhibitor). Indeed, this new class of drugs to manage HF, supported by the recent results and a vast clinical development programme, may prompt a conceptual shift in the treatment of HF, moving from the inhibition of RAAS and SNS to a more integrated target to rebalance neurohormonal dysregulation in HF.

Indexed as

AnimalsCardiotonic AgentsHeart FailureHumansNatriuretic PeptidesCardiotonic AgentsNatriuretic Peptidesbradykininheart failureLCZ696 (sacubitril/valsartan)natriuretic peptidesneprilysinneuroendocrine syndrome

Identifiers

PMID26637405
PMCPMC5233571
OpenAlexW2195459026

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.